Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02603146 · ClinicalTrials.gov registry record · Phase 2
Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
NCT02603146 is a Phase 2 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 144 participants.
The verdict
NCT02603146, a Phase 2 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if hydroxychloroquine (HCQ) is safe and effective for the prevention of future onset of rheumatoid arthritis (RA) in individuals who have elevations of an autoantibody, anti-cyclic citrullinated peptide (anti-CCP3). The following recruitment strategies will be employed towards identifying healthy subjects with elevated anti-cyclic citrullinated peptide (anti-CCP3) levels: -Pre-screening: * first degree relatives of patients with rheumatoid arthritis (RA); * subjects at health-fairs; and * identification of subjects with elevated anti-CCP3 levels in the absence of inflammatory arthritis in rheumatology clinics.
Interventions
- DRUG Hydroxychloroquine
- DRUG HCQ Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2016-04-27 |
| Est. Completion | 2022-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02603146
The ClinicalTrials.gov registry entry for NCT02603146 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hydroxychloroquine is the first listed.
NCT02603146 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02603146 about?
NCT02603146 is a clinical study titled "Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis". The purpose of this study is to determine if hydroxychloroquine (HCQ) is safe and effective for the prevention of future onset of rheumatoid arthritis (RA) in individuals who have elevations of an autoantibody, anti-cyclic citrullinated peptide (anti-CCP3). The following recruitment strategies will...
What is the current status of trial NCT02603146?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2016-04-27. Estimated completion is 2022-11-01.
What interventions are being tested in trial NCT02603146?
The interventions under investigation include: Hydroxychloroquine (DRUG), HCQ Placebo (DRUG).
Who is sponsoring clinical trial NCT02603146?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.